Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?

Neurobiology of Disease

Volumn 84, Issue , 2015, Pages 69-77

  Barone, Eugenio ^a   Butterfield, D Allan ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aging; Alzheimer disease; Heme oxygenase; Insulin resistance; Oxidative stress

Indexed keywords

HEME OXYGENASE 1; HEME OXYGENASE 2; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR;

ALZHEIMER DISEASE; CELLULAR STRESS RESPONSE; CYTOKINE RELEASE; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HIPPOCAMPUS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPID PEROXIDATION; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SPINAL CORD INJURY; ANIMAL; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; HEME OXYGENASE-1; HUMANS; INSULIN RESISTANCE;

EID: 84924678620     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.02.013     Document Type: Review

References (128)

1. Agarwal A., Nick H.S. Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression. J. Am. Soc. Nephrol. 2000, 11:965-973.
2. Akter K., Lanza E.A., Martin S.A., Myronyuk N., Rua M., Raffa R.B. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br. J. Clin. Pharmacol. 2011, 71:365-376.
3. Alzheimer's Association Early-Onset Dementia: A National Challenge, a Future Crisis., Washington D.C.. 2006.
4. Alzheimer's Association Alzheimer's Disease - Facts and Figures http://www.alz.org/downloads/Facts_Figures_2014.pdf.
5. Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans. Curr. Protein Pept. Sci. 2009, 10:96-107.
6. Barone E., Trombino S., Cassano R., Sgambato A., De Paola B., Di Stasio E., Picci N., Preziosi P., Mancuso C. Characterization of the S-denitrosylating activity of bilirubin. J. Cell. Mol. Med. 2009, 13:2365-2375.
7. Barone E., Di Domenico F., Cenini G., Sultana R., Cini C., Preziosi P., Perluigi M., Mancuso C., Butterfield D.A. Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim. Biophys. Acta 2011, 1812:480-487.
8. Barone E., Di Domenico F., Cenini G., Sultana R., Coccia R., Preziosi P., Perluigi M., Mancuso C., Butterfield D.A. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J. Alzheimers Dis. 2011, 25:623-633.
9. Barone E., Di Domenico F., Sultana R., Coccia R., Mancuso C., Perluigi M., Butterfield D.A. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic. Biol. Med. 2012, 52:2292-2301.
10. Barone E., Mancuso C., Di Domenico F., Sultana R., Murphy M.P., Head E., Butterfield D.A. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J. Neurochem. 2012, 120:135-146.
11. Barone E., Di Domenico F., Butterfield D.A. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem. Pharmacol. 2014, 88:605-616.
12. Barone E., Di Domenico F., Mancuso C., Butterfield D.A. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol. Dis. 2014, 62:144-159.
13. Bishop A., Yet S.F., Lee M.E., Perrella M.A., Demple B. A key role for heme oxygenase-1 in nitric oxide resistance in murine motor neurons and glia. Biochem. Biophys. Res. Commun. 2004, 325:3-9.
14. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest. 2012, 122:1339-1353.
15. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
16. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
17. Butterfield D.A., Reed T., Newman S.F., Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 2007, 43:658-677.
18. Butterfield D.A., Galvan V., Lange M.B., Tang H., Sowell R.A., Spilman P., Fombonne J., Gorostiza O., Zhang J., Sultana R., Bredesen D.E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 2010, 48:136-144.
19. Butterfield D.A., Barone E., Di Domenico F., Cenini G., Sultana R., Murphy M.P., Mancuso C., Head E. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int. J. Neuropsychopharmacol. 2012, 15:981-987.
20. Butterfield D.A., Swomley A.M., Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013, 19:823-835.
21. Butterfield D.A., Di Domenico F., Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim. Biophys. Acta 2014, 1842:1693-1706.
22. Butterfield D.A., Di Domenico F., Swomley A.M., Head E., Perluigi M. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem. J. 2014, 463:177-189.
23. Cai Z., Zhao B., Ratka A. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neruomol. Med. 2011, 13:223-250.
24. Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida Stella A.M., Galli F., Butterfield D.A. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 2003, 25:437-444.
25. Calabrese V., Sultana R., Scapagnini G., Guagliano E., Sapienza M., Bella R., Kanski J., Pennisi G., Mancuso C., Stella A.M., Butterfield D.A. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 2006, 8:1975-1986.
26. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007, 8:766-775.
27. Chiang H.C., Wang L., Xie Z., Yau A., Zhong Y. PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7060-7065.
28. Cholerton B., Baker L.D., Craft S. Insulin, cognition, and dementia. Eur. J. Pharmacol. 2013, 719:170-179.
29. Clark T.A., Lee H.P., Rolston R.K., Zhu X., Marlatt M.W., Castellani R.J., Nunomura A., Casadesus G., Smith M.A., Lee H.G., Perry G. Oxidative stress and its implications for future treatments and management of Alzheimer disease. Int. J. Biomed. Sci. 2010, 6:225-227.
30. Corrada M.M., Brookmeyer R., Paganini-Hill A., Berlau D., Kawas C.H. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann. Neurol. 2010, 67:114-121.
31. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26(Suppl. 1):65-69.
32. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168.
33. De Felice F.G. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 2013, 123:531-539.
34. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272.
35. De Felice F.G., Lourenco M.V., Ferreira S.T. How does brain insulin resistance develop in Alzheimer's disease?. Alzheimers Dement. 2014, 10:S26-S32.
36. de la Monte S.M. Insulin resistance and Alzheimer's disease. BMB Rep. 2009, 42:475-481.
37. de la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 2014, 88:548-559.
38. Dennery P.A. Signaling function of heme oxygenase proteins. Antioxid. Redox Signal. 2014, 20:1743-1753.
39. Di Domenico F., Coccia R., Butterfield D.A., Perluigi M. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim. Biophys. Acta 2011, 1814:1785-1795.
40. Di Domenico F., Barone E., Mancuso C., Perluigi M., Cocciolo A., Mecocci P., Butterfield D.A., Coccia R. HO-1/BVR-a system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease. J. Alzheimers Dis. 2012, 32:277-289.
41. Di Domenico F., Barone E., Perluigi M., Butterfield D.A. Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. Expert. Rev. Neurother. 2014, 1-22.
42. Dore S. Decreased activity of the antioxidant heme oxygenase enzyme: implications in ischemia and in Alzheimer's disease. Free Radic. Biol. Med. 2002, 32:1276-1282.
43. Dore S., Takahashi M., Ferris C.D., Zakhary R., Hester L.D., Guastella D., Snyder S.H. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2445-2450.
44. Dunn L.L., Midwinter R.G., Ni J., Hamid H.A., Parish C.R., Stocker R. New insights into intracellular locations and functions of heme oxygenase-1. Antioxid. Redox Signal. 2014, 20:1723-1742.
45. Durante W. Targeting heme oxygenase-1 in vascular disease. Curr. Drug Targets 2010, 11:1504-1516.
46. Durante W. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Front. Biosci. (Landmark Ed.) 2011, 16:2372-2388.
47. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr. Alzheimer Res. 2009, 6:213-223.
48. Frolich L., Blum-Degen D., Bernstein H.G., Engelsberger S., Humrich J., Laufer S., Muschner D., Thalheimer A., Turk A., Hoyer S., Zochling R., Boissl K.W., Jellinger K., Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. 1998, 105:423-438.
49. Fujisawa Y., Sasaki K., Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol. Psychiatry 1991, 30:1219-1228.
50. Gerbitz K.D., Gempel K., Brdiczka D. Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 1996, 45:113-126.
51. Ghasemi R., Haeri A., Dargahi L., Mohamed Z., Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol. Neurobiol. 2013, 47:145-171.
52. Gupta A., Lacoste B., Pistel P.J., Ingram D.K., Hamel E., Alaoui-Jamali M.A., Szarek W.A., Vlahakis J.Z., Jie S., Song W., Schipper H.M. Neurotherapeutic effects of novel HO-1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease. J. Neurochem. 2014, 131:778-790.
53. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
54. Hascalovici J.R., Vaya J., Khatib S., Holcroft C.A., Zukor H., Song W., Arvanitakis Z., Bennett D.A., Schipper H.M. Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenase-1. J. Neurochem. 2009, 110:1241-1253.
55. Havrankova J., Schmechel D., Roth J., Brownstein M. Identification of insulin in rat brain. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:5737-5741.
56. Hebert L.E., Beckett L.A., Scherr P.A., Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 2001, 15:169-173.
57. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013, 80:1778-1783.
58. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., Butterfield D.A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65:2146-2156.
59. Horwood J.M., Dufour F., Laroche S., Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur. J. Neurosci. 2006, 23:3375-3384.
60. Hosick P.A., Stec D.E. Heme oxygenase, a novel target for the treatment of hypertension and obesity?. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302:R207-R214.
61. Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural Transm. 2002, 109:991-1002.
62. Hsu Y.Y., Chen C.S., Wu S.N., Jong Y.J., Lo Y.C. Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells. Eur. J. Pharm. Sci. 2012, 46:415-425.
63. Jais A., Einwallner E., Sharif O., Gossens K., Lu T.T., Soyal S.M., Medgyesi D., Neureiter D., Paier-Pourani J., Dalgaard K., Duvigneau J.C., Lindroos-Christensen J., Zapf T.C., Amann S., Saluzzo S., Jantscher F., Stiedl P., Todoric J., Martins R., Oberkofler H., Muller S., Hauser-Kronberger C., Kenner L., Casanova E., Sutterluty-Fall H., Bilban M., Miller K., Kozlov A.V., Krempler F., Knapp S., Lumeng C.N., Patsch W., Wagner O., Pospisilik J.A., Esterbauer H. Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell 2014, 158:25-40.
64. Kapitulnik J., Maines M.D. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci. 2009, 30:129-137.
65. Kim T.S., Pae C.U., Yoon S.J., Jang W.Y., Lee N.J., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Decreased plasma antioxidants in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2006, 21:344-348.
66. Kimpara T., Takeda A., Yamaguchi T., Arai H., Okita N., Takase S., Sasaki H., Itoyama Y. Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease. Neurobiol. Aging 2000, 21:551-554.
67. Lebovitz H.E. Insulin resistance: definition and consequences. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2):S135-S148.
68. Lin Y., Vreman H.J., Wong R.J., Tjoa T., Yamauchi T., Noble-Haeusslein L.J. Heme oxygenase-1 stabilizes the blood-spinal cord barrier and limits oxidative stress and white matter damage in the acutely injured murine spinal cord. J. Cereb. Blood Flow Metab. 2007, 27:1010-1021.
69. Lourenco M.V., Clarke J.R., Frozza R.L., Bomfim T.R., Forny-Germano L., Batista A.F., Sathler L.B., Brito-Moreira J., Amaral O.B., Silva C.A., Freitas-Correa L., Espirito-Santo S., Campello-Costa P., Houzel J.C., Klein W.L., Holscher C., Carvalheira J.B., Silva A.M., Velloso L.A., Munoz D.P., Ferreira S.T., De Felice F.G. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. Cell Metab. 2013, 18:831-843.
70. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 2001, 22:187-194.
71. Lu D.Y., Chen J.H., Tan T.W., Huang C.Y., Yeh W.L., Hsu H.C. Resistin protects against 6-hydroxydopamine-induced cell death in dopaminergic-like MES23.5 cells. J. Cell. Physiol. 2013, 228:563-571.
72. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A., Cole G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009, 29:9078-9089.
73. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 1997, 37:517-554.
74. Maines M.D. The heme oxygenase system and its functions in the brain. Cell. Mol. Biol. (Noisy-le-grand) 2000, 46:573-585.
75. Maines M.D. The heme oxygenase system: update 2005. Antioxid. Redox Signal. 2005, 7:1761-1766.
76. Maines M.D. New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 2005, 20:382-389.
77. Maines M.D. Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings. Curr. Drug Targets 2010, 11:1586-1594.
78. Maines M.D., Panahian N. The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions?. Adv. Exp. Med. Biol. 2001, 502:249-272.
79. Mancuso C., Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr. Drug Metab. 2009, 10:579-594.
80. Mancuso C., Barone E., Guido P., Miceli F., Di Domenico F., Perluigi M., Santangelo R., Preziosi P. Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro. Neurosci. Lett. 2012, 518:101-105.
81. Mancuso C., Siciliano R., Barone E., Preziosi P. Natural substances and Alzheimer's disease: from preclinical studies to evidence based medicine. Biochim. Biophys. Acta 2012, 1822:616-624.
82. Mark R.J., Lovell M.A., Markesbery W.R., Uchida K., Mattson M.P. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 1997, 68:255-264.
83. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
84. Marrazzo G., Bosco P., La Delia F., Scapagnini G., Di Giacomo C., Malaguarnera M., Galvano F., Nicolosi A., Li Volti G. Neuroprotective effect of silibinin in diabetic mice. Neurosci. Lett. 2011, 504:252-256.
85. Mishra M., Ndisang J.F. A critical and comprehensive insight on heme oxygenase and related products including carbon monoxide, bilirubin, biliverdin and ferritin in type-1 and type-2 diabetes. Curr. Pharm. Des. 2014, 20:1370-1391.
86. Molina J.A., Jimenez-Jimenez F.J., Hernanz A., Fernandez-Vivancos E., Medina S., de Bustos F., Gomez-Escalonilla C., Sayed Y. Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease. J. Neural Transm. 2002, 109:1035-1044.
87. Molina J.A., Jimenez-Jimenez F.J., Vargas C., Gomez P., de Bustos F., Gomez-Escalonilla C., Zurdo M., Tallon A., Martinez-Salio A., Porta-Etessam J., Villanueva C., Arenas J. Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol. Scand. 2002, 106:347-350.
88. Moreira P.I. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J. Alzheimers Dis. 2012, 30(Suppl. 2):S199-S215.
89. Moreira P.I., Santos M.S., Selca R., Oliveira C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J. Neurol. Sci. 2007, 257:206-214.
90. Motterlini R., Foresti R. Heme oxygenase-1 as a target for drug discovery. Antioxid. Redox Signal. 2014, 20:1810-1826.
91. Mueller C., Zhou W., Vanmeter A., Heiby M., Magaki S., Ross M.M., Espina V., Schrag M., Dickson C., Liotta L.A., Kirsch W.M. The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1081-1091.
92. Nakatsuka I., Maeda S., Andoh T., Hayashi Y., Mizuno R., Higuchi H., Miyawaki T. Oxidative changes in the rat brain by intraperitoneal injection of ferric nitrilotriacetate. Redox Rep. 2009, 14:109-114.
93. Ndisang J.F. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediat. Inflamm. 2010, 2010:359732.
94. Neumann K.F., Rojo L., Navarrete L.P., Farias G., Reyes P., Maccioni R.B. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 2008, 5:438-447.
95. Pereira P.J., Macedo-Ribeiro S., Parraga A., Perez-Luque R., Cunningham O., Darcy K., Mantle T.J., Coll M. Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat. Struct. Biol. 2001, 8:215-220.
96. Perluigi M., Pupo G., Tramutola A., Cini C., Coccia R., Barone E., Head E., Butterfield D.A., Di Domenico F. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim. Biophys. Acta 2014, 1842:1144-1153.
97. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J., Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
98. Plum L., Schubert M., Bruning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 2005, 16:59-65.
99. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:478-493.
100. Qin W., Bauman W.A., Cardozo C. Bone and muscle loss after spinal cord injury: organ interactions. Ann. N. Y. Acad. Sci. 2010, 1211:66-84.
101. Reddy V.P., Zhu X., Perry G., Smith M.A. Oxidative stress in diabetes and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:763-774.
102. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 2005, 8:247-268.
103. Schipper H.M. Heme oxygenase-1 in Alzheimer disease: a tribute to Moussa Youdim. J. Neural Transm. 2011, 118:381-387.
104. Schipper H.M., Gupta A., Szarek W.A. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr. Alzheimer Res. 2009, 6:424-430.
105. Sena L.A., Chandel N.S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 2012, 48:158-167.
106. Seshadri S., Wolf P.A., Beiser A., Au R., McNulty K., White R., D'Agostino R.B. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 1997, 49:1498-1504.
107. Sharma H.S., Nyberg F., Gordh T., Alm P., Westman J. Neurotrophic factors influence upregulation of constitutive isoform of heme oxygenase and cellular stress response in the spinal cord following trauma. An experimental study using immunohistochemistry in the rat. Amino Acids 2000, 19:351-361.
108. Shin J.A., Lee J.H., Lim S.Y., Ha H.S., Kwon H.S., Park Y.M., Lee W.C., Kang M.I., Yim H.W., Yoon K.H., Son H.Y. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J. Diabetes Investig. 2013, 4:334-343.
109. Smith M.A., Richey P.L., Taneda S., Kutty R.K., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1994, 738:447-454.
110. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9866-9868.
111. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-Is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
112. Stocker R. Antioxidant activities of bile pigments. Antioxid. Redox Signal. 2004, 6:841-849.
113. Sultana R., Robinson R.A., Lange M.B., Fiorini A., Galvan V., Fombonne J., Baker A., Gorostiza O., Zhang J., Cai J., Pierce W.M., Bredesen D.E., Butterfield D.A. Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis?. Antioxid. Redox Signal. 2012, 17:1507-1514.
114. Swomley A.M., Forster S., Keeney J.T., Triplett J., Zhang Z., Sultana R., Butterfield D.A. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim. Biophys. Acta 2014, 1842:1248-1257.
115. Takahashi M., Snyder S.H. Interaction of amyloid precursor proteins and heme oxygenase. Alzheimer Dis. Assoc. Disord. 2000, 14(Suppl. 1):S67-S71.
116. Takahashi M., Dore S., Ferris C.D., Tomita T., Sawa A., Wolosker H., Borchelt D.R., Iwatsubo T., Kim S.H., Thinakaran G., Sisodia S.S., Snyder S.H. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 2000, 28:461-473.
117. Takeda A., Itoyama Y., Kimpara T., Zhu X., Avila J., Dwyer B.E., Perry G., Smith M.A. Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid. Redox Signal. 2004, 6:888-894.
118. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
119. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. U. S. A. 1968, 61:748-755.
120. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of hemoglobin to bilirubin. Trans. Assoc. Am. Phys. 1969, 82:363-371.
121. Tenhunen R., Marver H.S., Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J. Biol. Chem. 1969, 244:6388-6394.
122. Tsiftsoglou A.S., Tsamadou A.I., Papadopoulou L.C. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol. Ther. 2006, 111:327-345.
123. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
124. Wadman M. US government sets out Alzheimer's plan. Nature 2012, 485:426-427.
125. Wegiel B., Nemeth Z., Correa-Costa M., Bulmer A.C., Otterbein L.E. Heme oxygenase-1: a metabolic nike. Antioxid. Redox Signal. 2014, 20:1709-1722.
126. Yet S.F., Layne M.D., Liu X., Chen Y.H., Ith B., Sibinga N.E., Perrella M.A. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J. 2003, 17:1759-1761.
127. Zhang X., Shan P., Jiang D., Noble P.W., Abraham N.G., Kappas A., Lee P.J. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 2004, 279:10677-10684.
128. Zhao W.Q., Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 2009, 1792:482-496.